What is RNXT's market cap?

$59.12M, based on the Nov 4 close of $1.31.

Does RenovoRx pay a dividend?

No regular cash dividend has been paid in the last year.

How much of RNXT is sold short?

864.6K shares, 2.0% of float, as of Oct 15, 2026.

What sector is RNXT in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · RNXTHealthcarePharmaceuticals

RenovoRx, Inc. Common Stock (RNXT)

$1.31+1.55%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1.29▲ 18.35% in range

Nov 3, 2025Low $0.73 · High $2.52Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

RenovoRx closed at $1.31 on Nov 4, up 1.55%, 48.0% below its 52-week closing high. Volume of 217.5K shares was 0.56× its 20-day average (below normal).

Split-adjusted performance: -5.8% over one month, +47.2% over six months, +20.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $909K, up 115.4% from a year earlier, with a net margin of -320.2%.

Short interest was 864.6K shares at the Oct 15 settlement, down 8.7% from the prior report (2.0% of float, 1.6 days to cover).

Market cap$59.1M45.1M shares

Revenue · quarter$909.0K+115.4% YoY

Diluted EPS$-0.06—

P/E · TTM—P/S 29.9×

Net margin-320.2%Gross 84.3%

Dividend yieldNone

52-week range0.73 – 2.52−48.0% from high

Volume217.5K0.56× 20-day avg

Volatility · 60d108.4%Annualised

Short % of float2.0%1.6 days to cover

Net cash$9.5MCash $9.5M

Next earnings—Not scheduled

Split-adjusted performance

1W −8.1%1M −5.8%3M +13.9%6M +47.2%YTD +55.9%1Y +20.2%3Y +31.0%5Y −75.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum92

Revenue growth86

Net margin32

Value (low P/E)—

Size34

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short864.6K−8.7% vs prior

Days to cover1.6Settled Oct 15

% of float2.0%

Short vol. 10d66.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
RNXTRenovoRx	$1.31	+1.55%	+47.2%	+115.4%	−320.2%	—	$59.1M
VRCAVerrica Pharmaceuticals	$3.46	+5.02%	−59.0%	−53.8%	−224.4%	—	$59.4M	Compare
XBITXBiotech	$1.95	−2.01%	−23.5%	—	—	—	$59.5M	Compare
CLNNClene	$4.10	+8.75%	−42.7%	+233.3%	−14915.6%	—	$58.3M	Compare
NMADNomad Power Solutions	$3.60	+2.27%	—	—	—	—	$58.0M	Compare
CTORCitius Oncology	$0.5470	−0.55%	−39.8%	—	−597.4%	—	$57.9M	Compare
GOSSGossamer Bio	$9.95	+7.22%	−64.5%	−19.6%	182.9%	—	$60.9M	Compare
XLOXilio Therapeutics	$8.71	+0.35%	+10.3%	+131.2%	−34.1%	—	$57.3M	Compare
RNTXRein Therapeutics	$0.6587	−1.32%	−43.7%	—	—	—	$56.8M	Compare

News about RenovoRx

All news →

RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026GlobeNewswire Inc. · Apr 1, 2026▲ Positive

Quick answers

What does RenovoRx do?: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
What is RNXT's market cap?: $59.12M, based on the Nov 4 close of $1.31.
Does RenovoRx pay a dividend?: No regular cash dividend has been paid in the last year.
How much of RNXT is sold short?: 864.6K shares, 2.0% of float, as of Oct 15, 2026.
What sector is RNXT in?: Healthcare, in the Pharmaceuticals industry.

About RenovoRx

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

HQ: Mountain View, CA17 employeesListed Aug 26, 2021renovorx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology